H Lundbeck B receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
H Lundbeck B (0ND5)
H Lundbeck B stock price live, this page displays CSE HLUNb stock exchange data. View the HLUNb premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the H Lundbeck B real time stock price chart below.
What Is the H Lundbeck B Stock Price Today?
The H Lundbeck B stock price today is 35.34.
What Is the Stock Symbol for H Lundbeck B?
The stock symbol for H Lundbeck B is ""HLUNb.""
What Stock Exchange Does H Lundbeck B Trade On?
H Lundbeck B is listed and trades on the Copenhagen stock exchange.
Is H Lundbeck B a Good Stock to Buy?
Determining whether H Lundbeck B—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HLUNb quote. (ISIN: DK0061804770)
What Is the H Lundbeck B Stock Price Today?
The H Lundbeck B stock price today is 35.34.
What Is the Stock Symbol for H Lundbeck B?
The stock symbol for H Lundbeck B is ""HLUNb.""
What Stock Exchange Does H Lundbeck B Trade On?
H Lundbeck B is listed and trades on the Copenhagen stock exchange.
Is H Lundbeck B a Good Stock to Buy?
Determining whether H Lundbeck B—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HLUNb quote. (ISIN: DK0061804770)
35.34
+0.12(+0.34%)
Closed·
Fair Value
An estimate of a H Lundbeck B's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
35.10
35.60
52 wk Range
27.20
49.38
0ND5 Scorecard
Full Analysis
Has raised its dividend for 3 consecutive years
0ND5 is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a H Lundbeck B's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
35.1035.60
52 wk Range
27.2049.38
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
0ND5 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a H Lundbeck B's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
- H Lundbeck B receives Investment Bank Analyst Rating Update
- Investing.com
Pro - H Lundbeck B receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- H Lundbeck B receives Investment Bank Analyst Rating Update
- Investing.com
Pro - H Lundbeck B receives Investment Bank Analyst Rating Update
- Investing.com
Pro - H Lundbeck B receives Investment Bank Analyst Rating Update
- Investing.com
Pro - H Lundbeck B receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
H Lundbeck B Company Profile
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. The company was founded in 1915 and is headquartered in Valby, Denmark.
Compare 0ND5 to Peers and Sector
Metrics to compare | 0ND5 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship0ND5PeersSector | |
|---|---|---|---|---|
P/E Ratio | 10.3x | 22.4x | −0.5x | |
PEG Ratio | 0.28 | 0.17 | 0.00 | |
Price/Book | 1.4x | 2.8x | 2.6x | |
Price / LTM Sales | 1.5x | 2.5x | 3.2x | |
Upside (Analyst Target) | - | 6.6% | 41.7% | |
Fair Value Upside | Unlock | 13.8% | 6.1% | Unlock |
Earnings
Latest Release
May 13, 2025
EPS / Forecast
1.16 / 0.7784
Revenue / Forecast
6.24B / 5.77B
People Also Watch
FAQ
What Stock Exchange Does H Lundbeck B Trade On?
H Lundbeck B is listed and trades on the London Stock Exchange stock exchange.
What Is the Stock Symbol for H Lundbeck B?
The stock symbol for H Lundbeck B is "0ND5."
What Is the H Lundbeck B Market Cap?
As of today, H Lundbeck B market cap is 33.89B.
What Is H Lundbeck B's Earnings Per Share (TTM)?
The H Lundbeck B EPS (TTM) is 3.32.
When Is the Next H Lundbeck B Earnings Date?
H Lundbeck B will release its next earnings report on 19 Aug 2025.
From a Technical Analysis Perspective, Is 0ND5 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has H Lundbeck B Stock Split?
H Lundbeck B has split 0 times.
How Many Employees Does H Lundbeck B Have?
H Lundbeck B has 5700 employees.
What is the current trading status of H Lundbeck B (0ND5)?
As of 26 Jul 2025, H Lundbeck B (0ND5) is trading at a price of 35.34, with a previous close of 173.73. The stock has fluctuated within a day range of 35.10 to 35.60, while its 52-week range spans from 27.20 to 49.38.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.